Mark C. McKenna

Bio:

Mark C. McKenna is a renowned biotech entrepreneur, executive, and director known for his exceptional leadership and visionary approach. Mirador is a next-generation precision medicine company focused on developing first-in-class or best-in-class precision medicines for immunology and inflammation. Launched in 2024, Mirador has raised over $400 million from leading life sciences investors and is based in San Diego, CA.

Prior to Mirador, Mr. McKenna served as Chairman, President, and CEO of Prometheus Biosciences from 2019 until its acquisition by Merck for $10.8 billion in June 2023. Under his leadership, Prometheus raised over $1 billion in private and public financing, was recognized as the top-performing biotech IPO of 2021, and pioneered the first precision therapeutics clinical trial for immune-mediated diseases. This led to its acquisition by Merck, resulting in the largest buyout of a company with a pre-Phase 3 asset to date.

Prior to Prometheus, Mr. McKenna was the President of Salix Pharmaceuticals and a corporate officer at Bausch + Lomb. There, he revitalized the gastroenterology business through strategic acquisitions and product launches, doubling revenue to over $2 billion and significantly enhancing operating margins. He also spent over a decade at Bausch + Lomb, where he was SVP and General Manager of the US Vision Care business.

Mr. McKenna began his career at Johnson & Johnson, where he held several positions of increasing responsibility. He currently serves as the Chairman of Apogee Therapeutics, Inc. and is a board member of Spyre Therapeutics, Inc. and New Amsterdam Pharma. In addition, Mr. McKenna is a Venture Partner at Arch and Senior Advisor to Fairmount Funds. Mr. McKenna holds a B.S. in marketing from Arizona State University and an MBA from Azusa Pacific University. Mr. McKenna also completed the Wharton’s Fellows Program at the University of Pennsylvania School of Business.